News

HeartForce introduced the Electromechanical Risk (EMR) Score at the prestigious CinC2023 conference held in Atlanta. Computing in Cardiology Conference, a globally recognized scientific symposium, provides a platform for experts in the fields of medicine, physics, engineering, and computer science to disseminate their cutting-edge research in clinical cardiology and cardiovascular physiology. The EMR Score’s debut at… Continue reading EMR Score Introduced at the Computing in Cardiology Conference

Hearforce’s design team optimized the next generation of CardioClin which featured a more ergonomic shape and improved usability. The narrower shape allows a better fit for both female and male users. The small disposable electrode patch lets the sensor be easy to apply and sanitize.

HeartForce has developed the Electromechanical Risk (EMR) Score, a groundbreaking AI-powered tool for precise cardiac risk assessment in coronary artery disease (CAD) screening. Leveraging seismocardiography (SCG) data and clinical variables, the EMR Score offers a non-invasive, data-driven approach to screen CAD risk. The use of SCG enhances patient comfort and convenience during screening. The EMR… Continue reading Finalization of HeartForce proprietary EMR-Score-Algorithm

Heartforce’s Afib detection algorithm was tested on a large database of 84k cases with an accuracy equivalent to current FDA approved algorithms. Afib detection will be deployed on future CardioClin and CardioPro products and will be ready for Health Canada and FDA submissions.

HeartForce has embarked on Phase 1 of a Verification Study in Uzbekistan. This significant undertaking follows the successful development of the EMR Score in a prior study. In this new phase, HeartForce is in the process of acquiring a comprehensive verification database, meticulously designed to closely resemble the characteristics of the actual target population. This… Continue reading HeartForce starts Phase 1 of Verification Study in Uzbekistan

HeartForce filed a patent application in the United States for monitoring patients after coronary angioplasty.  The provisional patent was assigned the application number U.S. 63/459960.  Meanwhile, the company will be conducting a one-year clinical study through the monitoring patients pre and post stent surgery

HeartForce is proud to announce that it has successfully completed the entire data collection process in Uzbekistan consisting of: (1) patients with high levels of coronary artery disease (Stenosis of ≥ 50% in at least one coronary artery), (2) a healthy and age-matched control group and (3) patients with mild to medium levels of occlusion… Continue reading Fifth HeartForce Update on the CardioClin Multi-Center Study in Uzbekistan

HeartForce has successfully filed a continuation application at the United States Patent and Trademark Office on November 21, 2022: “Sensor apparatuses, methods of operating same and systems including same and methods and systems for sensing and analyzing electromechanical characteristics of a heart” In accordance with our instructions, the continuation application was assigned application number 17/991,523.… Continue reading HeartForce files Continuation of United States Patent Application

HeartForce’s scientific team in Uzbekistan has collected in-depth data for developing an algorithm to screen for coronary artery disease (CAD). The study has been divided into three phases. In phase 1, we collected a total of 1,530 patients’ data to investigate the ability to use machine learning algorithms to predict the presence of CAD. Most… Continue reading Fourth HeartForce Update on the Cardio Clin Multi-Center Study in Uzbekistan

The objective of our study is to enhance the accuracy of the Q-wave detection to handle abnormal ECG signal patterns more accurately. Q-wave detection is a significant factor for segmenting the cardiac vibrational signal for coronary artery disease (CAD) detection. By identifying the abnormal ECG signal segment (e.g., caused by Afib, premature contraction, movement artifacts,… Continue reading HeartForce Commences Automatic Improvement of ECG Processing Methods

In spring of 2022, our development team updated the design of our CardioClin for improved user ergonomics. The new design has an inverted heart shape which is attached to the sternum using a standard ECG adhesive electrode. It has two ports for the “right-arm” and “left-leg” ECG leads. A light indicator is located on the… Continue reading HeartForce Introduces CardioClin 2.0

As reported in November of 2021, HeartForce has successfully completed the data collection of 1500 patients, suspected of having coronary artery disease (CAD), in the clinical trial in Uzbekistan. The dataset consisted of the following two datasets: Tashkent Patients and Karshi Patients Tashkent Control Group The first data set consisted of patients that were suspected… Continue reading Third HeartForce Update on the CardioClin Multi-Center Study in Uzbekistan

Presenting a non-invasive solution to identify patients with coronary artery disease (CAD) defined as less than 50% stenosis in at least one coronary artery. In this study, the cardio-mechanical activity of the patients’ hearts were recorded during rest, using seismocardiography (SCG) and gyrocardiography (GCG). Our findings clearly indicate that our CAD models based on SCG… Continue reading Frontiers Publication: Detecting Coronary Artery Disease Using Rest Seismocardiography and Gyrocardiography

HeartForce has successfully completed the data collection of 1500 patients, suspected of having coronary artery disease (CAD), in the clinical trial in Uzbekistan. Seismocardiography and gyrocardiography, for a non-invasive CAD diagnosis, were compared to coronary artery calcium computed tomography (CAC-CT), coronary computed tomography (CCTA), and invasive coronary angiography (ICA). The datasets were collected between the… Continue reading Second HeartForce Update on the Cardio Clin Multi-Center Study in Uzbekistan

HeartForce is pleased to announce that it has successfully collected datasets for 250 patients in their clinical trial in Uzbekistan. Seismocardiography and gyrocardiography, for a non-invasive coronary artery disease (CAD) diagnosis, were compared to coronary artery calcium computed tomography (CAC), coronary computed tomography (CCTA), and invasive coronary angiography (ICA).

HeartForce is pleased to announce its latest multi-center study, to occur at the end of March 2021, in Uzbekistan. The research study will take place in coordination with three renowned heart centres, located in Tashkent and Karshi. The study will involve 1500 enrolled patients and will be supervised by the Eurasian Heart Foundation (EAHF), headquartered… Continue reading HeartForce to Commence CardioClin Multicenter Study in Uzbekistan

HeartForce is pleased to present a report of its latest studies and results for identifying patients with coronary artery disease (CAD) using seismocardiography (SCG). The findings of this study tested the performance of HeartForce SCG technology in identifying patients with CAD compared to other methods, including ECG stress test and coronary computed tomography angiography (CCTA).… Continue reading HeartForce CAD Report – Seismocardiography: A Reliable Screening Method to Detect Coronary Artery Disease

HeartForce received the 5th place prize out of 2648 companies from 118 countries at the K-Start Grand Challenge in South Korea. Minister Park Young-sun and the Ministry of SMEs and Startups (MSS), South Korea, presented the award to HeartForce at a special Gala Dinner in Seoul. The first five teams received government grants and were… Continue reading HeartForce Wins Award Over 2600 Companies at the K-Start Grand Challenge

HeartForce has reached the final round of the 2020 Swiss Innovation Challenge. The challenge is both an innovation funding program and competition, organized by the Chamber of Commerce of Baselland, the University of Applied Sciences and Arts Northwestern Switzerland (FHNW) and the Basellandschaftliche Kantonalbank (BLKB). Twenty-five finalists and one winner will be selected from over… Continue reading HeartForce Enters the Final Round Receives an Award Nomination in the 2020 Swiss Innovation Challenge

Heart Force has been accepted as one of the Top 60 participant teams for the 2020 K-Startup Grand Challenge (KSGC) in Korea. HeartForce was selected from over 2600 applicants from 118 countries.  The K-Startup Grand Challenge is a Korean government-led initiative that supports talented local and international tech companies and entrepreneurs with the goal of… Continue reading HeartForce Accepted for 2020 Korea Grand Challenge Accelerator

Essential for monitoring cardiac performance is the assessment of cardiac time intervals (CTIs). With the introduction of gyrocardiography (GCG) as a non-invasive technology for cardiac monitoring, HeartForce investigates the accuracy and reproducibility of estimating CTIs from the GCG recordings of 50 adults.

HeartForce receives ‘Gold’ at German Innovation Awards 2020, with the presentation of the world’s first complete heart-screening device for the early detection and prevention of heart disease. As a leader in innovation and honouring both products and solutions that distinguish themselves primarily by their user centricity, the German Innovation Awards recognized the HeartForce Cardio Pro… Continue reading Cardio Pro Achieves Gold Standard

Using a combination of seismocardiogram (SCG) and electrocardiogram (ECG), HeartForce conducts an analysis on the repeatability of systolic time intervals (STIs) in healthy subjects via two experiments.

Using rest and exercise seismocardiography, HeartForce presents a non-invasive methodology in helping to identify coronary artery disease (CAD), and combating the most common cause of death worldwide. Discover how the fast, easy and inexpensive SCG examination compares to more traditional CAD assessments of exercise electrocardiography (ECG), coronary angiography and coronary computed tomography angiography (CCTA).

Heart force attended the Computing in Cardiology Conference 2019, Singapore, Singapore and presented the results of study “Estimation of Cardiac Time Intervals from the Mechanical Activity of the Heart Using Machine Learning.”

In clinical examinations, HeartForce investigated the reliability of cardiac time intervals and beat-to-beat extraction of PCG, ICG and SCG signals in relation to the clinical gold standard of multimodal echocardiography (Doppler, TDI, and M-mode). The three non-invasive methodologies possess the potential to be embedded in wearable devices (ICG, SCG, and PCG), and detect clinically relevant… Continue reading HeartForce Investigates Use of PCG, ICG and SCG in Wearable Devices to Detect Cardiac Time Intervals

To investigate the effects of the coronary artery disease on the morphology of the SCG and GCG waveforms, HeartForce designed and conducted an investigational study in the University Hospital Zürich, Switzerland. One hundred and fifty patients participated in this study, who were suspected of having coronary artery disease and were referred to the hospital for… Continue reading HeartForce Investigational Study – University Hospital of Zürich, Switzerland

To investigate the morphology of the SCG and GCG waveforms, Heart force designed and conducted an investigational study in Simon Fraser University in Vancouver, Canada. One hundred individuals in the 40-85 age range were recruited for this study.

HeartForce Medical Inc. held its annual general meeting on August 31, 2017, electing four new board members. Dr. Kouhyar Tavakolian, Dr. Geoff Houlton, Kay Jessel, and Dr. Erwin Bauer were all elected to the board. Beat Naegeli now serves as the chair and Jennie Choboter is Secretary.  Kay Jessel was appointed by the newly-elected board… Continue reading New Board Members Appointed to HeartForce Medical’s Board of Directors